N/A N=52 Music for Pain in Primary Dysmenorrhea
Pain, Menstrual · Primary Dysmenorrhea
Primary: Change in Pain From 1-5 Minutes Before (Baseline) to 1- 5 Minutes After the Intervention — -1.85; -0.18 cm — p=0.002
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=507 Effect on Primary Dysmenorrhea
Primary Dysmenorrhea
Primary: Change Between Baseline Evaluation Period and Treatment Evaluation Period in the Number of Days With Dysmenorrheic Pain — -4.6; -4.2 Days
Phase 2 N=280 Effect of KYG0395 on Primary Dysmenorrhea
Primary Dysmenorrhea
Primary: The Change From Baseline to the End of Treatment Period in Maximum Dysmenorrheic Pain VAS Score — -19.8; -18.0; -14.4 units on a scale — p=>0.05
Phase 3 N=88 Low-level Light Therapy for Primary Dysmenorrhea
Primary Dysmenorrhea
Primary: Dysmenorrheal Pain Severity — 3.88; 6.31 units on a scale
Phase 3 N=249 SH T00186 Phase II/ III Optimal Drospirenone (DRSP) Dose Finding and Placebo-controlled Comparative Study
Dysmenorrhea
Primary: Change From Baseline in Total Dysmenorrheal Score at Final Evaluation — -2.5; -2.1; -1.9; -1.0 scores on a scale — p=<0.001
Phase 3 N=215 Efficacy and Safety Study of NPC-01 to Treat Dysmenorrhea
Dysmenorrhea
Primary: Patient Response to Treatment for Dysmenorrhea, as Evaluated by Difference of Total Dysmenorrhea Score (Baseline/Pretreatment-End of Treatment) — 4.1; 4.2; 1.8; 2.9…
N/A N=44 Effectiveness of Nanoone Woman Underwear Using in the Management of Dysmenorrhea
Dysmenorrhea
Primary: The Mean Change in Maximum Pain Level at Each Menstrual Cycle From Baseline — -0.810; -1.29; -1.74 scores
Phase 3 N=115 Efficacy and Safety Study of Low Dose Oral Contraceptive Pill to Treat Primary Dysmenorrhea
Dysmenorrhea
Primary: Patient Response to Treatment for Primary Dysmenorrhea, as Evaluated by Difference of Total Dysmenorrhea Score (Baseline/Pretreatment-End of Treatment) — 3.8; 3.6; 1.2…
Phase 3 N=139 Study to Assess the Safety and Efficacy of Etoricoxib Versus Ibuprofen in the Treatment of Dysmenorrhea (MK-0663-145 AM1)
Dysmenorrhea
Primary: Total Pain Relief Score Over the First 6 Hours (TOPAR6) After the Initial Dose — 17.38; 16.49 Score on a Scale — p=0.043
Phase 2 N=38 Continuous Administration of Oral Contraceptive, Primary Dysmenorrhea
Dysmenorrhea
Primary: Change in Visual Analog Scale (VAS) Score — -74.8; -58.7 units on a scale — p=0.05
Phase 3 N=420 Safety Study of Ethinylestradiol/Drospirenone in Dysmenorrhea
Dysmenorrhea
Primary: Number of Participants With Intracyclic Bleeding at Cycle 6 — 40; 4 participants
Phase 2 N=84 Efficacy and Safety Study of Lidocaine Vaginal Gel for Recurrent Dysmenorrhea (Painful Periods)
Dysmenorrhea
Primary: The Primary Efficacy Variable Will be the Time-weighted Average Pain Intensity Over 4 Treatment Days Using the 4 Point Categorical Scale. — 0.91; 0.92 units on a scale
Phase 2 N=25 Viagra in the Treatment of Primary Dysmenorrhea
Dysmenorrhea
Primary: The Primary Outcome Was Total Pain Relief Over 4 Hours (TOPAR4), Comparing a Single Dose of Sildenafil 100 mg to a Single Dose of Placebo. — 11.9; 6.4 units on a scale…
Phase 2 N=439 A Study to Evaluate the Effect of Contraceptive Vaginal Rings on Primary Dysmenorrhea (P08257/MK-8175A/MK-8342B-057)
Dysmenorrhea
Primary: Change From Baseline in Mean Menstrual Cramping Pain Score Through Cycle 2 — -1.7; -1.7; -1.9; -1.7 Units on a scale — p=< 0.001
Phase 4 N=353 Chronic Pain Risk Associated With Menstrual Period Pain
Cystitis, Interstitial · Dysmenorrhea · Migraine Disorders
Primary: Change in Participant Bladder Pain Sensitivity From Baseline. — 38.2; 37.0; 41.2; 47.9 score on a scale — p=.02
Phase 4 N=201 A Study to Assess Menstrual Cramp Pain Associated With Primary Dysmenorrhea
Dysmenorrhea
Primary: Sum of Total Pain Relief (TOTPAR) Over 0-12 Hours — 29.18; 24.87 Scores on a scale * hours — p=< 0.001
Phase 3 N=149 Efficacy and Safety, Long-Term Study of NPC-01 to Treat Dysmenorrhea Associated With Endometriosis
Dysmenorrhea
Primary: Patient Response to Treatment for Dysmenorrhea, as Evaluated by Difference of Total Dysmenorrhea Score (Baseline/Pretreatment-End of Treatment) — 2.4 units on a scale
Phase 4 N=26 Examining the Role of Improved NSAID Management in Treating Dysmenorrhea and Bladder Pain
Dysmenorrhea · Pain
Primary: Change in Menstrual Pain — 4.1 score on a scale — p=<0.0001
N/A N=102 A Comparison Study of Pain Relief From Dysmenorrhea Between the Vipon Tampon and Ibuprofen
Dysmenorrhea
Primary: Percentage of Intervention Uses That Resulted in at Least 1 Point Decrease in Pain and Requiring no Rescue Medication Using the Modified Melzack-McGill Scale Using a…
Phase 2 N=10 Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study
Endometriosis
Primary: Change in Score in Worst Pain Over the Last Month — -0.5; -5 score on a scale
N/A N=56 Dyspareunia and Central Sensitization
Endometriosis · Central Sensitisation · Dyspareunia
Primary: Deep Dyspareunia Score — 3.08 scores on a scale
N/A N=104 Quality of Life in Premenopausal Women With Heavy Menstrual Bleeding
Heavy Menstrual Bleeding
Primary: Hot Flush Frequency Total Score (HFRS) Change — 9.3; 8.8; 12.7 score on a scale
Phase 4 N=1 Ulipristal for Endometriosis-related Pelvic Pain
Endometriosis
Primary: Pelvic Pain — 3.5; 0.2; 3.9 units on a scale — p=<0.05
Phase 2 N=95 A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain
Dysmenorrhea
Primary: Mean Change in Average Severity for Abdominal/Pelvic Pain — -0.45; -0.19 units on a scale
Phase 2 N=22 Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain
Endometriosis-related Pain
Primary: Changes in the Mean Daily Numerical Rating Scale (NRS) Scores for the Worst Endometriosis-related Pain. — -0.66; -2.04; -2.14; -3.68 score on a scale
Phase 4 N=250 Pain Control In First Trimester Medical Abortion: A Randomized Trial
Pain
Primary: 11-point Visual Analog Scale for Pain — 7.1; 7.3 units on a scale
Phase 3 N=872 A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain
Endometriosis
Primary: Percentage of Responders at Month 3 Based on Daily Assessment of Dysmenorrhea (DYS) — 19.6; 46.4; 75.8 percentage of participants — p=< 0.001
Phase 4 N=44 Resveratrol for Pain Due to Endometriosis
Endometriosis
Primary: Pain Scores Measured by VAS (Visual Analog Scale) at Day 42. — 3.2; 3.9 units on a scale — p=0.7
Phase 3 N=504 Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With Moderate to Severe Endometriosis-Associated Pain
Endometriosis
Primary: Percentage of Participants With a Response for Dysmenorrhea at Month 6 Based on Daily Assessment — 52.1; 78.2; 32.6; 64.4 percentage of participants
Phase 4 N=28 Copper IUD Treatment Observation Study
Menorrhagia
Primary: Mean Days of Bleeding and Spotting, Spotting Only and Bleeding Only for the 84 Day Treatment Cycles and Last 28 Day Post-treatment Cycle — 29.2; 23.0; 9.3; 9.6 days…